Home » USA Broker Ratings » Novo Nordisk A/S – Consensus Indicates Potential 7.1% Upside

Novo Nordisk A/S – Consensus Indicates Potential 7.1% Upside

Novo Nordisk A/S found using ticker (NVO) now have 2 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 72 and 69.45 with the average target price sitting at 70.72. With the stocks previous close at 66.04 this indicates there is a potential upside of 7.1%. There is a 50 day moving average of 65.11 and the 200 day moving average is 61.33. The market cap for the company is $152,689m. You can visit the company’s website by visiting: http://www.novonordisk.com

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. It also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson’s diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio to develop in vivo genome editing treatments for genetic diseases. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Join us on our new LinkedIn page

Follow us on LinkedIn